Ultragenyx Pharmaceutical reported $220.64M in Current Liabilities for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Liabilities Change
Acadia Pharmaceuticals ACAD:US $ 117.68M 1.92M
Agios Pharmaceuticals AGIO:US $ 48.4M 2.6M
Alnylam Pharmaceuticals ALNY:US $ 657.68M 51.72M
Aptinyx Inc APTX:US $ 5.68M 945K
Biomarin Pharmaceutical BMRN:US $ 464.73M 25.69M
Bluebird Bio BLUE:US $ 148.86M 5.97M
Epizyme EPZM:US $ 34.95M 4.01M
Esperion Therapeutics ESPR:US $ 82.28M 3.19M
Insmed INSM:US $ 113.82M 11.43M
IONIS PHARMACEUT IONS:US $ 267.81M 39.36M
Karyopharm Therapeutics KPTI:US $ 62.54M 3.8M
Kyowa Hakko Kirin 4151:JP Y 103507M 13040M
Macrogenics MGNX:US $ 50.88M 16.22M
Mirati Therapeutics MRTX:US $ 119.15M 4.42M
Moderna Inc MRNA:US 6.81B 2.43B
Neurocrine Biosciences NBIX:US $ 285.7M 32.2M
Ptc Therapeutics PTCT:US $ 567.37M 90.6M
Puma Biotechnology PBYI:US $ 56.83M 17.95M
Regeneron Pharmaceuticals REGN:US $ 3033.9M 26.3M
Sarepta Therapeutics SRPT:US $ 545.57M 90.6M
Ultragenyx Pharmaceutical RARE:US $ 220.64M 53.4M
Vertex Pharmaceuticals VRTX:US $ 2556.2M 376M
Vital Therapies VTL:US $ 10.4M 1.06M
Xoma XOMA:US $ 8.42M 534K